Scholar Rock的萎缩症药物与Eli Lilly的Zepbound联合使用时，在减肥研究中显示出约55%更好的肌肉保存效果-动脉网

Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study

benzinga 等信源发布 2025-06-18 10:47



可切换为仅中文







Scholar Rock

学者岩

SRRK

revealed results on Wednesday from the Phase 2 EMBRAZE proof-of-concept trial assessing apitegromab in combination with tirzepatide to preserve lean mass during tirzepatide-

周三公布了评估apitegromab与tirzepatide联合使用以在tirzepatide治疗期间保持瘦体质量的2期EMBRAZE概念验证试验的结果。

induced weight loss

诱导减重

。

Tirzepatide is an active ingredient in

Tirzepatide 是一种活性成分在

Eli Lilly And Co’s

礼来公司

LLY

礼来公司

widely used Mounjaro and Zepbound for diabetes and weight loss, respectively.

广泛用于糖尿病和减肥的Mounjaro和Zepbound。

The trial demonstrated that 30% of the total weight loss with tirzepatide alone was

该试验表明，单独使用替西帕肽可使总体重减轻30%。

due to lean mass loss

由于瘦体质量损失

。

Apitegromab therapy (10 mg/kg) with tripeptide preserved an additional 4.2 pounds (1.9 kilograms) or 54.9% (p=0.001) of lean mass compared to tripeptide alone, leading to higher-quality weight loss.

Apitegromab治疗（10 mg/kg）与三肽联用，相比单独使用三肽，额外保留了4.2磅（1.9公斤）或54.9%的瘦体质量（p=0.001），从而实现了更高质量的体重减轻。

Also Read:

另请阅读：

Scholar Rock Stock Jumps On Additional Data From Pivotal Trial Of Muscular Dystrophy Treatment

Scholar Rock股票因肌肉萎缩症治疗关键试验的更多数据而上涨

The study showed that 30.2% of the total weight loss with tirzepatide, the ingredient in Zepbound, was due to lean mass loss.

研究显示，Zepbound中的成分替尔泊肽导致的总体重减轻中有30.2%源于瘦体重的减少。

According to 24-week data, adding 10 mg/kg apitegromab therapy to the tripeptide regimen halved the proportion of lean mass lost to 14.6%.

根据24周的数据，将10 mg/kg的apitegromab治疗加入三肽方案中，瘦体质量损失比例减少了一半，降至14.6%。

The company described the apitegromab-tirzepatide combo as 'higher quality of weight loss.' Specifically, these patients lost 85% and 15% of their fat and lean mass, respectively, while the ratio for the tirzepatide-placebo cohort was 70% and 30%.

公司形容 apitegromab-tirzepatide 的组合为“更高质量的减重”。具体来说，这些患者分别减掉了 85% 的脂肪和 15% 的瘦体重，而 tirzepatide-安慰剂组的比例分别为 70% 和 30%。

Regarding total weight loss, patients on apitegromab-tirzepatide saw their weight drop by 12.3% compared to 13.4% for those on tirzepatide-placebo.

关于总体重减轻，使用apitegromab-tirzepatide的患者体重下降了12.3%，而使用tirzepatide-placebo的患者体重下降了13.4%。

Apitegromab with tirzepatide was generally well tolerated by participants.

Apitegromab与tirzepatide的组合通常被参与者良好耐受。

Earlier in June,

早在六月，

Regeneron Pharmaceuticals, Inc.

再生元制药公司

REGN

再生元制药（Regeneron Pharmaceuticals）

released interim results from the ongoing Phase 2 COURAGE trial investigating combinations of

发布了正在进行的二期COURAGE试验的中期结果，该试验研究的是组合疗法

Novo Nordisk A/S

诺和诺德公司

NVO

Wegovy (semaglutide) (GLP-1 receptor agonist) and trevogrumab (anti-GDF8/anti-myostatin) with or without garetosmab

Wegovy（司美格鲁肽）（GLP-1受体激动剂）和特雷沃单抗（抗GDF8/抗肌肉生长抑素），联合或不联合加雷托单抗

(anti-activin A) for obesity

（抗激活素A）用于肥胖症

。

The trial demonstrated that approximately 35% of semaglutide-induced weight loss was due to loss of lean mass.

试验表明，大约35%的司美鲁肽减重效果是由于瘦体重的减少。

Last week,

上周，

Juvena Therapeutics Inc.

尤文纳治疗公司

announced

宣布

global licensing and multi-target research collaboration with Eli Lilly. The two companies aim to develop and commercialize drug candidates that improve

全球许可和多靶点研究合作与礼来公司。两家公司旨在开发和商业化改进的候选药物。

muscle health and body composition

肌肉健康和身体成分

。

Price Action:

价格行为:

SRRK stock is up 18% at $36.77 at the last check on Wednesday.

SRRK股票在周三最后一次检查时上涨了18%，达到36.77美元。

加载中...

Read Next:

接下来阅读：

Eli Lilly Launches Flat Pricing For Zepbound, Capping Monthly Cost At $499